Cardiovascular physiology: Recent acquisitions;Physiologie cardiovasculaire les nouvelles donnes

Archives des Maladies du Coeur et des Vaisseaux

Volumn 95, Issue 4, 2002, Pages 299-304

  Swynghedauw, B ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR FUNCTION; CLINICAL PRACTICE; FRANCE; GENE EXPRESSION; HEART FAILURE; HUMAN; HUMAN GENOME; PHARMACOGENETICS; REVIEW;

CARDIOVASCULAR PHYSIOLOGY; GENE EXPRESSION REGULATION; GENOME, HUMAN; HEART; HUMANS; SOFTWARE;

EID: 0036233970     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Homeostasis, humpy dumpty, and integrative biology
2. Are physiologists ready for the new physiology?
3. Initial sequencing and analysis of the human genome
4. The sequence of the human genome
5. Cardiovascular genomics: Estimating the total number of genes expressed in the human cardiovascular system
6. Functional genomics: It's all how you read it
7. Applications of proteomics to the study of cardiovascular biology
8. Functional genomics and physialogy: A natural fit
9. Utility of genetic approaches to common cardiovascular diseases
10. Heart transplantation changes the expression of distinct gene families
11. Suitability criteria for manuscripts utilizing genomics array technoloqy
12. Special emphasis panel on integrative research
13. Decreased heart rate variability in transgenic mice overexpressing atrial beta 1-adrenoceptors
14. Exploring the new world of the genome with DNA microarrays
15. Making and reading microarrays
16. Resequencing and mutational analysis using oligonucleotide microarrays
17. Molecular mechanisms of myocardial remodeling
18. The Physiome Project in unclerstanding the heart: The Cardiame
19. Transgenic models of myocardial dysfunction
20. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice
21. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy
22. Physiological effects of inverse agonists in transgenic mice with myocarcdial overexpression of the beta 2-adrenoceptor
23. A genome-based resource for molecular cardiovascular medicine. Toward a compendium of cardiovascular genes
24. Gene expression profiles in normal and cancer cells
25. The future of genetic studies of complex human diseases
26. The heart SNPs a beat: Polymorphisms in candidate genes for cardiovascular disease
27. Sequence diversity in 36 candidate genes for cardiovascular disorders
28. Exploring the metabolic and genetic contral of gene expression on a genomic scale
29. Parallel human genome analysis: Microarray-based expression monitoring of 1 000 genes
30. Pharmacogenetics: Translating functional genomics into rational therapeutics
31. Altered patterns of gene expression in response to myocardial infarction
32. Application of the cDNA microarrays in determining molecular phenotype in cardiac growth, development and response to injury
33. Tangled up in blue. Molecular cardiology in the postmolecular area
34. A genomic perspective on protein families
35. Diagnostic d'une cardiomyopathie hypertrophique. Validation des critères par la génétique
36. Genetic and molecular basis of cardiac arrhythmias. Impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology
37. Polymarphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exist?
38. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions
39. Gene expression in distinct regions of the heart
40. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone
41. Stereoselective disposition of carvedilol is determined by CYP2D6
42. Oxidation phenotype. A major determinant of metoprolol metabolism and response
43. *4 allele on the pharmacokinetics of controlled-release metoprolol
44. Cordiovascular pharmocogenetics and pharmacogenomics
45. Antihypertensive pharmacogenetics: Getting the right drug into the right patient
46. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition
47. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
48. The apolipoprotein epsilon 4 allele determines prognosis and the effect on prognosis of simvastatin in survivars of myocardial infarction. A substudy of the Scandinavian Simvastatin Survival Study
49. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
50. High risk of cerebral-vein thrombosis in corriers of a prothrombin-gene mutation and in users of oral contraceptives
51. Bradykinin B2 receptor gene polymorphism is associated with angiotensine-converting enzyme inhibitor-related cough
52. Susceptibility-conferring polymorphic enotypes in cardiovascular multifactorial syndromes